| Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer (NCT00371345) | Bristol-Myers Squibb | 2006-12-01 |
| A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer (NCT00371254) | Bristol-Myers Squibb | 2006-12-01 |
| A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis (NCT00484289) | Bristol-Myers Squibb | 2006-12-01 |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL (NCT00349518) | Bristol-Myers Squibb | 2006-12-01 |
| Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients (NCT00384904) | Bristol-Myers Squibb | 2006-12-01 |
| A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer (NCT00332748) | Bristol-Myers Squibb | 2006-12-01 |
| A Study of BMS-562086 in Patients With Irritable Bowel Syndrome (NCT00399438) | Bristol-Myers Squibb | 2006-12-01 |
| A Study of Abatacept in Patients With Active Ulcerative Colitis (NCT00410410) | Bristol-Myers Squibb | 2006-12-01 |
| A Study of Abatacept in Patients With Active Crohn's Disease (NCT00406653) | Bristol-Myers Squibb | 2006-12-01 |
| Drug Interaction - Oral Contraceptive (NCT00399685) | Bristol-Myers Squibb | 2006-12-01 |
| Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects (NCT00388609) | Bristol-Myers Squibb | 2006-11-01 |
| Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (NCT00371683) | Bristol-Myers Squibb | 2006-11-01 |
| Bioequivalence Study of Atazanavir 300 mg Capsule (NCT00393328) | Bristol-Myers Squibb | 2006-11-01 |
| Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection (NCT00371150) | Bristol-Myers Squibb | 2006-11-01 |
| A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug (NCT00382668) | Bristol-Myers Squibb | 2006-10-01 |
| Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone (NCT00362726) | Bristol-Myers Squibb | 2006-09-01 |
| Abatacept Pregnancy Exposure Registry (NCT01087125) | Bristol-Myers Squibb | 2006-09-01 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer (NCT00971867) | Bristol-Myers Squibb | 2006-08-04 |
| Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase (NCT00324077) | Bristol-Myers Squibb | 2006-08-01 |
| Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (NCT00324155) | Bristol-Myers Squibb | 2006-08-01 |
| A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies (NCT00441337) | Bristol-Myers Squibb | 2006-08-01 |
| Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib (NCT00320190) | Bristol-Myers Squibb | 2006-08-01 |
| A Study of the Alternative Administration of Ixabepilone and Vinflunine (NCT00362830) | Bristol-Myers Squibb | 2006-08-01 |
| A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors (NCT00329004) | Bristol-Myers Squibb | 2006-08-01 |
| Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin (NCT00779428) | Bristol-Myers Squibb | 2006-07-01 |
| Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) (NCT00352560) | Bristol-Myers Squibb | 2006-07-01 |
| Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer) (NCT00359450) | Bristol-Myers Squibb | 2006-07-01 |
| Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects (NCT00357188) | Bristol-Myers Squibb | 2006-07-01 |
| Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females (NCT00357604) | Bristol-Myers Squibb | 2006-07-01 |
| A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer (NCT00320255) | Bristol-Myers Squibb | 2006-06-01 |
| Drug Interaction Study With Proton Pump Inhibitor (NCT00357240) | Bristol-Myers Squibb | 2006-06-01 |
| Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women (NCT00326716) | Bristol-Myers Squibb | 2006-06-01 |
| Factors Associated With Biologic DMARD Switching (NCT02346942) | Bristol-Myers Squibb | 2006-06-01 |
| A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate (NCT00345748) | Bristol-Myers Squibb | 2006-06-01 |
| Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer (NCT00344552) | Bristol-Myers Squibb | 2006-06-01 |
| Atazanavir Twice Daily (NCT00357721) | Bristol-Myers Squibb | 2006-06-01 |
| Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (NCT00337467) | Bristol-Myers Squibb | 2006-06-01 |
| A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer (NCT00326586) | Bristol-Myers Squibb | 2006-05-01 |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma (NCT00357461) | Bristol-Myers Squibb | 2006-05-01 |
| Safety Study of Apixaban in Recent Acute Coronary Syndrome (NCT00313300) | Bristol-Myers Squibb | 2006-05-01 |
| A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (NCT00162123) | Bristol-Myers Squibb | 2006-05-01 |
| A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (NCT00289627) | Bristol-Myers Squibb | 2006-04-01 |
| Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (NCT00289640) | Bristol-Myers Squibb | 2006-04-01 |
| A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer (NCT00326131) | Bristol-Myers Squibb | 2006-04-01 |
| Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty (NCT00344045) | Bristol-Myers Squibb | 2006-04-01 |
| Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies (NCT00300027) | Bristol-Myers Squibb | 2006-04-01 |
| Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir (NCT00365339) | Bristol-Myers Squibb | 2006-04-01 |
| Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia (NCT00306202) | Bristol-Myers Squibb | 2006-03-31 |
| A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate (NCT00298987) | Bristol-Myers Squibb | 2006-02-01 |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma (NCT00298467) | Bristol-Myers Squibb | 2006-02-01 |
| Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects (NCT02262520) | Bristol-Myers Squibb | 2006-01-01 |
| A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis (NCT00295282) | Bristol-Myers Squibb | 2006-01-01 |
| Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (NCT00323882) | Bristol-Myers Squibb | 2006-01-01 |
| BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies (NCT00207051) | Bristol-Myers Squibb | 2006-01-01 |
| Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) (NCT00254293) | Bristol-Myers Squibb | 2006-01-01 |
| Rollover Study of BMS-354825 in Patients With CML and Ph+ALL (NCT01030718) | Bristol-Myers Squibb | 2006-01-01 |
| Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy (NCT00803556) | Bristol-Myers Squibb | 2006-01-01 |
| Study of BMS-663513 in Patients With Advanced Cancer (NCT00309023) | Bristol-Myers Squibb | 2005-12-01 |
| A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (NCT00135408) | Bristol-Myers Squibb | 2005-12-01 |
| Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study (NCT00978731) | Bristol-Myers Squibb | 2005-12-01 |
| Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin (NCT00773344) | Bristol-Myers Squibb | 2005-12-01 |
| BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada (NCT00272779) | Bristol-Myers Squibb | 2005-11-01 |
| Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background (NCT00162292) | Bristol-Myers Squibb | 2005-11-01 |
| Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) (NCT00207142) | Bristol-Myers Squibb | 2005-11-01 |
| Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder (NCT00135421) | Bristol-Myers Squibb | 2005-11-01 |
| Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome (NCT00110422) | Bristol-Myers Squibb | 2005-11-01 |
| A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease (NCT00284804) | Bristol-Myers Squibb | 2005-11-01 |
| Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) (NCT00261365) | Bristol-Myers Squibb | 2005-11-01 |
| Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study (NCT00252005) | Bristol-Myers Squibb | 2005-11-01 |
| Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer (NCT00855764) | Bristol-Myers Squibb | 2005-10-01 |
| Effect of Ketoconazole on the Pharmacokinetics of Vinflunine (NCT00388557) | Bristol-Myers Squibb | 2005-10-01 |
| ATV/Ritonavir Nevirapine Interaction (USPAC) (NCT00162149) | Bristol-Myers Squibb | 2005-10-01 |
| Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone (NCT00119678) | Bristol-Myers Squibb | 2005-09-01 |
| Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes (NCT00106808) | Bristol-Myers Squibb | 2005-08-01 |
| Study of Dasatinib in Patients With Advanced Solid Tumors (NCT00162214) | Bristol-Myers Squibb | 2005-08-01 |
| MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00112580) | Bristol-Myers Squibb | 2005-07-31 |
| Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome (NCT00135356) | Bristol-Myers Squibb | 2005-07-01 |
| Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML (NCT00123474) | Bristol-Myers Squibb | 2005-07-01 |
| Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan (NCT00337454) | Bristol-Myers Squibb | 2005-07-01 |
| Remission and Joint Damage Progression in Early Rheumatoid Arthritis (NCT00122382) | Bristol-Myers Squibb | 2005-07-01 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer (NCT00971945) | Bristol-Myers Squibb | 2005-06-30 |
| A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome (NCT00312754) | Bristol-Myers Squibb | 2005-06-01 |
| Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML (NCT00123487) | Bristol-Myers Squibb | 2005-06-01 |
| A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer (NCT00337532) | Bristol-Myers Squibb | 2005-05-01 |
| Study of BMS-587101 in Patients With Moderate to Severe Psoriasis (NCT00162253) | Bristol-Myers Squibb | 2005-04-01 |
| Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy (NCT00124982) | Bristol-Myers Squibb | 2005-04-01 |
| Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs (NCT00198289) | Bristol-Myers Squibb | 2005-04-01 |
| Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) (NCT01088360) | Bristol-Myers Squibb | 2005-03-31 |
| Safety Study of Abatacept to Treat Rheumatoid Arthritis (A) (NCT01088321) | Bristol-Myers Squibb | 2005-03-01 |
| Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) (NCT00256750) | Bristol-Myers Squibb | 2005-03-01 |
| Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (NCT00095147) | Bristol-Myers Squibb | 2005-02-01 |
| Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients (NCT00124449) | Bristol-Myers Squibb | 2005-02-01 |
| Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant (NCT00114777) | Bristol-Myers Squibb | 2005-02-01 |
| Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib (NCT00101660) | Bristol-Myers Squibb | 2005-02-01 |
| Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia (NCT00103844) | Bristol-Myers Squibb | 2005-02-01 |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT00101595) | Bristol-Myers Squibb | 2005-01-01 |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium (NCT00101608) | Bristol-Myers Squibb | 2005-01-01 |
| A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators (NCT00162448) | Bristol-Myers Squibb | 2005-01-01 |
| Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia (NCT00101647) | Bristol-Myers Squibb | 2004-12-01 |
| Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate (NCT00101816) | Bristol-Myers Squibb | 2004-12-01 |